Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the efficacy and safety of fruquintinib combined with mFOLFOX6 +
synchronous radiotherapy as neoadjuvant therapy in middle and low locally advanced rectal
cancer patients with no previous anti-tumor treatment.